Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon

Soo Ki Kim,Kim,Susumu Imoto,Madoka Tohyama,Yumi Otono,Tamura T,Ke Ih Kim,Mana Kobayashi,Aya Ohtani,Kayo Sugimoto,Mizuguchi A,Hiramatsu Y,Masatoshi Kudo

Recent Advances in the Management of Chronic Hepatitis B Including Suppression of Hepatocellular Carcinoma by Entecavir and Interferon

2015

Soo Ki Kim
Kim
Susumu Imoto
Madoka Tohyama
Yumi Otono
Tamura T
Ke Ih Kim
Mana Kobayashi
Aya Ohtani
Kayo Sugimoto
Mizuguchi A
Hiramatsu Y
Masatoshi Kudo

At present, for adults with chronic hepatitis B virus (HBV) infection, two new analogues, entecavir (ETV) and tenofovir, are recommended as the first-line therapy by the EASL (European Association for

Keywords:

Tenofovir
Hepatitis B
Immunology
Hepatocellular carcinoma
Medicine
Entecavir
Interferon
Hepacivirus
Hepatitis B virus
Virology
Virus
chronic hepatitis
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations